Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2020 | TKI therapy for pediatric ALL patients with ABL-class fusions

Anthony Moorman, PhD, Newcastle University, Newcastle, UK, discusses the results of his study investigating the impact of adjuvant tyrosine kinase inhibitor (TKI) therapy on pediatric acute lymphoblastic leukemia (ALL) patients with ABL-class fusions at the BSH 2020. Screening during UKALL2011 found that patients with ABL-class fusions had high levels or minimal residual disease (MRD) at the end of induction, which was associated with a high risk of relapse. Patients with post-induction MRD over 1% were given the adjuvant TKI, imatinib, plus standard chemotherapy, whilst an earlier cohort who were not screened prospectively received only standard chemotherapy. Patients who received imatinib had a lower risk of relapse compared to those who received standard chemotherapy alone. Prof. Moorman also outlines the upcoming ALLTogether1 trial (NCT03911128) which will screen all patients for ABL-class fusions at diagnosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).